Observ Medical

[TekBot]

Observe Medical - CFO resignation

Oslo, March 21, 2024 - Observe Medical ASA (the “Company” or “Observe Medical”)
announces that Per Arne Nygård has resigned from his position as CFO in order to
pursue opportunities outside of the Company.
…

Vis børsmeldingen

Johan Fagerli, the current Finance Manager, will assume the responsibilities of
Interim CFO effective immediately. Mr. Fagerli has been with the Company since
2021 and brings extensive experience and a deep understanding of our financial
operations, ensuring a smooth transition and continued strategic financial
management.

We look forward to Mr. Fagerli’s leadership in his new role as we continue to
execute our strategic objectives.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Finance Manager Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.

Kilde

[Quadruple]

Nygård virket å være en bra mann for selskapet. Men forståelig at han går for noe annet.

[Powertrade]

Kanskje april byr på nye kontrakter og spennende nyheter.

[TekBot]

Observe Medical transfers Nordic distribution to Vingmed

Oslo, April 18, 2024 - Observe Medical ASA (the “Company” or “Observe Medical”)
announces transfer of its Nordic distribution operations to Vingmed, following a
strategic review. The Company assessed the relevance of the business, originally
…

Vis børsmeldingen

established as a platform for testing and launching its branded products.

Given the expansion of our global distribution capabilities, which now fulfill
our initial testing and pre-launch needs, the business is becoming less crucial
to our core operations. Consequently, we have decided to seek more suitable
ownership of the Nordic operations going forward.

In November 2023, this decision aligned with the establishment of a new
distribution partnership agreement with Vingmed for the UnoMeterT portfolio in
the Nordic region. Subsequent to this agreement, we began confidential
discussions with Vingmed that resulted in a formal agreement to transfer our
Nordic distribution business to them. The planning for this transfer started in
late 2023 under strict confidentiality to safeguard the ongoing business
operations.

As we now approach the final stages of this transition, we are lifting the
confidentiality to transparently communicate with our stakeholders. The
completion of this transfer is anticipated by the second quarter of 2024. This
strategic divestiture aligns with Observe Medical’s broader objective to
streamline our operations and concentrate on expanding our international market
presence, thereby enhancing shareholder value and strengthening our competitive
position in the global market.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.

Kilde

[Powertrade]

Bra nyheter

Måtte kursen stige

Blir spennnede med 1Q salget

[Quadruple]

Hva synes du er bra?

[Powertrade]

This
strategic divestiture aligns with Observe Medical’s broader objective to
streamline our operations and concentrate on expanding our international market
presence, thereby enhancing shareholder value and strengthening our competitive
position in the global market.

[Quadruple]

@Powertrade

concentrate on expanding our international market
presence, thereby enhancing shareholder value and strengthening our competitive
position in the global market.

Er det noe nytt? “Svada” er vel en mer dekkende betegnelse. Observe har lovet “gull og grønne skoger” i flere år. Men har ikke levert noe som helst.

[Powertrade]

Ha en bedre dag

[Powertrade]

Nå begynner det å røre seg… Snart ser vi 1 krone- ca 100% opp dit…

[Powertrade]

Elsker Observe Medical- En fallert juvel som snart vil skinne igjen…

[Powertrade]

Herlig å være tidlig inne - Snart kommer bjellesauene…

[Quadruple]

Trodde det var du som var bjellesauen?

[Powertrade]

Ja - det ser slik ut- eller da er det bedre å kalles "bjelle lam "

[Powertrade]

[Quadruple]

Dette er gammelt nytt. Emisjonen ble ingen suksess, og selskapet trenger snart penger igjen.
Og dette vet du, Powertrade.

La oss slippe “Hegnar-tilstander” her.

[Powertrade]

Det er sant - gammel nytt - Så får vi håpe det genereres inntekter mer enn estimat.

Du håper på det du og Quadruple? For du eier aksjer i OBSERVE?

[Quadruple]

Har bare et lite antall. Som jeg hverken blir rik eller fattig av, uansett hvilken vei det går.

[Powertrade]

Et lite antall er jo relativt- Det kan være 50.000, 500.000 eller 5.000.000.

Jeg har et relativt stort antall - men det er jo og relativt.

Jeg blir relativt rik om det går rett vei !

Hva er forresten rikdom ?

[TekBot]

Observe Medical Annual Report for 2023

Oslo, 30 April 2024 - Observe Medical ASA (“the Company” or “Observe Medical”)
today announces that the Company has published its Annual Report for 2023. The
Annual Report was approved by the Board of Directors on 26 April 2024.
…

Vis børsmeldingen

“Despite some challenges, 2023 was a year of great achievements and exciting
opportunities. I am grateful for the dedication of the Observe Medical team and
the continued support of our shareholders. Our ambition and goals for the future
remain unchanged, and I look forward to updating you on our progress soon”
commented Jørgen Mann, Interim CEO of Observe Medical.

The Annual Report for 2023 is attached to this notice and available on the
Company’s website under the Investor Relations section. The auditor’s report,
which is incorporated in the annual report, includes a statutory emphasis of
matter relating to the further financing of the Company.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.

Kilde